High-Risk Pancreatic Surveillance: Does the Germline Mutation Matter Once an IPMN Appears?: JAMA Network | September 2026

What Did the Study Find?

This multicenter study followed 1,688 individuals with hereditary or familial pancreatic cancer risk across 25 centers.

• Presumed IPMNs were identified in 29.4% of participants.
• Among those without a cyst at baseline, 9.6% developed a new pancreatic cyst during surveillance.
• IPMN incidence and cyst-growth trajectories did not significantly differ across familial pancreatic cancer and pathogenic germline variant groups.
• Changes in main pancreatic duct diameter were also similar.
• Only 2.6% developed new worrisome features or high-risk stigmata.
• Importantly, median follow-up was only 17 months, limiting conclusions about longer-term gene-specific behavior.

Why Does It Matter?

Surveillance programs increasingly include individuals with BRCA, ATM, CDKN2A, Lynch syndrome and other inherited risks. Once a cyst is detected, clinicians must decide whether the underlying mutation itself should determine surveillance intensity.

GastroAGI Takeaway

Once an IPMN is present, what the cyst does may matter more than which gene brought the patient into surveillance. Morphology, ductal changes and interval growth may be more useful for guiding follow-up intensity than the specific germline mutation alone. However, 17 months is too short to exclude meaningful long-term gene-specific differences.